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Variations in serum markers of collagen production (CICP) and degradation (ICTP), insulin-like 
growth factor I (IGF-I) and anterior knee laxity (AKL) were measured in 20 women [10 with 
spontaneous cycles (eumenorrheic), 10 using oral contraceptives] over 5 consecutive days at 
menses (M1–M5, 1st pill week), the initial estrogen rise near ovulation (O1–O5, 2nd pill week), 
the initial progesterone rise of the early luteal phase (EL1–EL5, 3rd pill week) and post-
progesterone peak of the late luteal phase (LL1–LL5, 4th pill week). ICTP was higher in oral 
contraceptive women (5.3 ± 1.7 vs. 3.7 ± 1.3 µg/L; p = 0.030), primarily during days near 
ovulation and the early luteal phase when concentrations decreased in eumenorrheic women 
(p = 0.04). IGF-I concentrations increased during menses then decreased and remained lower 
during the early and late luteal phase in oral contraceptive women, resulting in lower 
concentrations compared to eumenorrheic women at EL2 and LL1 (p = 0.03). CICP decreased in 
early and late luteal days (p <0.01), and there was a trend toward lower concentrations in 
eumenorrheic versus oral contraceptive women (85.7 ± 35.7 ng/ml vs. 123.2 ± 49.8 ng/ml; 
p = 0.07). Lower CICP and greater IGF-I concentrations predicted greater AKL across the 20 
cycle days in both groups (R2 = 0.310 and 0.400). Sex hormone concentration changes across the 
menstrual cycle are of sufficient magnitude to influence collagen metabolism, and may indirectly 
influence knee structure and function. 
 




Cyclic increases in anterior knee laxity (AKL) observed across the menstrual cycle1–5 are of 
sufficient magnitude to alter knee joint biomechanics.37 While cyclic changes in sex hormone 
concentrations appear to partially mediate these effects5, 6 the underlying mechanisms remain 
unclear. This information is important as ACL injury risk may vary disproportionately across the 
menstrual cycle,16 with a higher than expected proportion of ACL injuries observed in the 
follicular phase around the time of menses7, 8 and ovulation9 (time points in the cycle where sex 
hormones are rapidly decreasing and increasing, respectively) compared to the luteal phase. 
 
AKL represents the combined resistance of the ligament, muscle, and capsule to a displacing 
load. While the ACL provides approximately 85% of the static restraint to anterior tibial 
translation,10 it is difficult to elucidate whether cyclic increases in AKL are specifically due to 
changes in the local metabolism and structure of the ligament, or due to other local factors. With 
that in mind, sex hormone receptors have been identified on the human ACL, and the effect of 
sex hormones (primarily estrogen) on collagen metabolism has been examined in both animal11, 
12 and human13, 14 ACLs, yielding conflicting results. In studies of human ACL tissue in cell 
culture,13, 14 progressive decreases in fibroblast proliferation and type 1 procollagen synthesis 
were observed as estradiol concentrations progressively increased. This decrease in collagen 
synthesis occurred regardless of progesterone concentration; however, the decrease was 
somewhat attenuated at higher progesterone concentrations.14 Further, these hormone effects 
were most pronounced immediately after hormone exposure (days 1 and 3), and attenuated with 
sustained exposure (7 days).14 While this led to the suggestion that acute fluctuations in hormone 
concentrations across a woman's menstrual cycle (specifically higher estradiol levels) have the 
potential to inhibit collagen synthesis and reduce ligament strength,14 they are largely limited to 
cell culture models that include both physiologic and supraphysiologic hormone concentrations. 
Research examining associations between sex hormones, collagen metabolism and ligament 
structure/behavior in physically active women who experience normal physiological fluctuations 
in sex hormone concentrations across the menstrual cycle are largely lacking.15 
 
Also unknown is whether oral contraceptives, commonly used by physically active women, 
minimize or exacerbate these potential associations. Depending on the type of oral contraceptive 
administered, the levels of exogenous estradiol and progesterone can be 3–5 times and 1–2 times 
higher, respectively, than normal endogenous levels.16 Women on oral contraceptives have been 
shown to have lower concentrations of serum and local markers of collagen production and 
degradation, and smaller collagen fibril diameter in tendons, together suggesting an inferior 
collagen structure.17–19 However, comparisons are limited to a single time point (mid luteal 
phase), which may not reflect concentrations at other times in the cycle.20 Comparisons are also 
limited to women using specific monophasic brands, and the influence of oral contraceptives 
may depend on the type administered (monophasic or triphasic), the concentration of ethinyl 
estradiol delivered, as well as the type, potency and androgenicity of the progestin compound 
delivered, which ultimately determines its ability to counteract the estrogenic effects.16 These 
differences among oral contraceptives may in part explain why studies comparing AKL in 
eumenorrheic women (normal menstruating women who are not using oral contraceptives) 
versus women using oral contraceptives are inconclusive.21, 22 These later comparisons were also 
based on a single measurement of AKL that was collected at a random time of the cycle (i.e., the 
hormone milieu was not controlled for). 
 
To begin to address these unknowns, our primary purpose was to initially determine whether 
normal physiological variations in hormone concentrations across the menstrual cycle are of 
sufficient magnitude to stimulate changes in collagen metabolism as measured by serum collagen 
markers and mediators. Specifically, we compared eumenorrheic women to women using oral 
contraceptives on daily changes in their insulin-like growth factor I (IGF-I; a mediator of 
collagen production23), C-terminal propeptide of collagen type-I (CICP; a direct marker of 
collagen production), and carboxyterminal telopeptide of type I collagen (ICTP; a direct marker 
of collagen degradation) concentrations over the course of one menstrual cycle. A secondary 
purpose was to examine whether cyclic changes in serum CICP, ICTP, and IGF-I were 
associated with cyclic changes in AKL within each group. While acknowledging that (1) the 
underlying physiological mechanisms for these associations are likely quite complex and involve 
more than type I collagen, and (2) that serum concentrations reflect changes in type I collagen 
from a variety of tissues (e.g., bone, ligament, etc.) and may or may not adequately represent the 
local environment of the ligament,17, 18 we felt this was a reasonable first step before moving on 
to more invasive sampling of collagen markers within the knee joint given the daily sampling 
required to achieve our primary purpose. Based on findings of prior research,14, 17–19 we 
hypothesized that concentrations of CICP, ICTP, and IGF-I would generally be lower in both 
groups during days of the cycle when estradiol levels were elevated, and that greater cyclic 
variations in CICP, ICTP, IGF-I, and AKL would be observed in eumenorrheic women versus 
those using oral contraceptives during and immediately following the peri-ovulatory days of the 
cycle (when estradiol is rising unopposed in eumenorrheic women). We further expected that 
individuals who experienced greater decreases in concentrations of CICP, ICTP, and IGF-I 
(suggesting reduced collagen synthesis and inferior collagen structure14, 18, 19) would experience 




Blood samples and AKL data were accessed from ten healthy, eumenorrheic women (23.5 ± 3.9 
years; 63.0 ± 9.7 kg; 163.0 ± 5.6 cm) measured daily across one complete menstrual cycle in a 
previous study.5, 6, 24 All had normal spontaneous menstrual cycles lasting 26–32 days that varied 
no more than ±1 day between months, and did not use oral contraceptives. They were compared 
to 10 women using oral contraceptives for at least 3 months (20.7 ± 2.2 years; 67.3 ± 8.5 kg; 
164.6 ± 5.4 cm) and underwent daily measurements identical to eumenorrheic women (see Table 
1 for details of oral contraceptives used). All subjects had healthy knees, were recreationally 
active 2½–10 h/week for the past 3 months, were non-smokers, had a body mass index 
(BMI = weight/height2) <30, and were otherwise free of known medical conditions or connective 
tissue disorders. All subjects signed an informed consent approved by the University's 




Blood samples (10 cc) were collected from the antecubital vein between 7:00 a.m. and 9:00 a.m. 
each morning to assay estradiol (DSL-4400, Diagnostic Systems Laboratories, Webster TX), 
progesterone (Coat-A-count, Diagnostic Products Corporation, Los Angeles, CA), testosterone 
(Coat-A-count; Diagnostic Products Corporation), IGF-I (IDS, Fountain Hills, AZ), CICP 
(Quidel, San Diego, CA), and ICTP (IDS). Assay sensitivity (unit value), and mean intra- and 
inter-assay percent coefficient of variations (%), respectively were 1.5 pg/ml, 3.9–14.1% and 
2.8–16.3% for estradiol; 0.1 ng/ml, 3.4–10.0% and 3.8–12.0% for progesterone; 10 ng/dl, 4.5–
11.3% and 5.2–13.8% for testosterone; 1.9 ng/ml, 3.0% and 7% for IGF-I; 0.2 ng/ml, 6.5% and 
6.1% for CICP; and 0.3 µg/L, 9.8% and 7.6% for ICTP. 
 
AKL was measured with the KT-2000 Knee Arthrometer (MedMetric Corp, San Diego, CA) as 
the anterior displacement of the tibia relative to the femur (mm) under an applied anterior 
directed load of 133 N. Three measures were recorded and averaged for each day. One tester 
completed all measures for a single subject. Because of the time lapse between studies, different 
testers measured AKL for eumenorrheic (T1) and oral contraceptive (T2) cohorts. Both were 
trained in an identical fashion, and established strong intra-tester reliability [T1 
ICC2,3(SEM) = 0.97 (0.38 mm); T2 ICC2,3 (SEM) = 0.96 (0.30 mm)] as well as strong inter-tester 
reliability with others trained in our laboratory [T1 ICC2,3 (SEM) = 0.92 (0.50); T2 
ICC2,3 (SEM) = 0.96 (0.5 mm)].4, 5 
 
To test the first hypothesis, daily CICP, ICTP, IGF-I, and AKL values were first aligned for 
eumenorrheic women based on their sex hormone concentrations for the first 5 days of menses 
(M1–M5) based on self report; the first 5 days of the initial estradiol rise near ovulation (O1–O5) 
based on a 2 SD increase above mean menses concentrations; the first 5 days of the early luteal 
phase (EL1–EL5) based on the initial rise in progesterone (>2 ng/ml); and the first 5 days of the 
late luteal phase (LL1–LL5) starting with the day of peak progesterone. Because women vary 
from one another in the timing and phasing of their hormone concentration changes5, aligning 
data in this manner ensured that the variables of interest were compared across women on days 
representative of a similar hormone milieu. For women using oral contraceptives, the CICP, 
ICTP, IGF-I, and AKL values obtained on the first 5 days of each pill week were used to 
represent their M1–M5, O1–O5, EL1–EL5, and LL1–LL5 test measures. The two groups were 
then compared across these 20 cycle days on their CICP, ICTP, IGF-I, and AKL values using a 
multivariate 2 (group) by 20 (cycle days) repeated measures ANOVA to control for type I error. 
Post hoc comparisons consisted of simple main effects testing. 
 
To test the second hypothesis, separate multiple, stepwise removal linear regression analyses 
determined the extent to which the daily change in the group mean values for CICP, ICTP, and 
IGF-I predicted daily change in AKL. CICP, ICTP, and IGF-I were first entered simultaneously, 
then variables were removed in a stepwise fashion (tolerance = 0.20) if they did not contribute 
significantly to the model.25Assuming that the patterns of change in variables would be different 
for eumenorrheic women versus those using oral contraceptives, separate analyses were run 




Mean endogenous hormones and collagen marker/mediator concentrations and anterior knee 
laxity are graphically displayed in Figure 1, stratified by group [note: current assay techniques do 
not allow for quantification of exogenous (synthetic) hormone concentrations delivered to oral 
contraceptive women, which are also biologically active]. The multivariate results were 
significant for cycle day and group by cycle day effects (p <0.001). Follow-up univariate results 
revealed significant differences between eumenorrheic and oral contraceptive women in their 
daily changes in ICTP, IGF-I, and AKL (all p <0.044), but not in their CICP (p = 0.266) 
(Figures 2–5). ICTP concentrations were stable in oral contraceptive women across cycle days 
(p = 0.174), but decreased in eumenorrheic women during days O2–EL1 and EL4 (p = 0.022). 
While ICTP concentrations were generally higher in oral contraceptive women (5.3 ± 1.7 µg/L 
vs. 3.7 ± 1.3 µg/L; p = 0.030), this difference was most pronounced during days of O and EL 
(p <0.05). IGF-I concentrations remained stable across days for eumenorrheic women 
(p = 0.558), but decreased in oral contraceptive women during days of EL and LL (p <0.001; 
Figure 3). This resulted in oral contraceptive users having lower IGF-I values than eumenorrheic 
women at EL2 and LL1 (p <0.05). CICP concentrations generally decreased in days of EL and 
LL compared to days of M and O (p < 0.001; Figure 4). While this change was similar across 
days for both groups, eumenorrheic women tended to have lower overall CICP concentrations 
than oral contraceptive women (85.7 ± 35.7 ng/ml vs. 123.2 ± 49.8 ng/ml; p = 0.07; 
Cohen's d = 1.1). Lastly, AKL was stable across days in oral contraceptive women (p = 0.429), 
but increased in eumenorrheic women during the first 3 days of EL, and days 2, 4, and 5 of LL 
(p = 0.029). 
 
When comparing patterns of variability between cycle days for CICP, ICTP, and IGF-I with 
AKL, bivariate correlations are listed in Table 2. For both groups, decreases in CICP 
concentrations and increases in IGF-I concentrations predicted increases in AKL across the 20 
days of the menstrual cycle, explaining 31% (p = 0.043) and 40% (p = 0.014) of the variance in 
eumenorrheic and oral contraceptive women, respectively (Figure 6). The final regression 
models were AKL = 4.95 − 0.014 (CICP) + 0.013 (IGF-I) for eumenorrheic women and 
AKL = 5.9 − 0.005 (CICP) + 0.006 (IGF-I) for oral contraceptive women. Change in ICTP 
concentrations was not a significant predictor in either model (part correlation 0.025 and 0.184, 
respectively, for eumenorrheic and oral contraceptive women; p >0.465), and was therefore 



















Eumenorrheic versus oral contraceptive women differed substantially in their daily changes in 
AKL, serum IGF-I (a mediator of collagen production) and ICTP (marker of type I collagen 
degradation) concentrations across the menstrual cycle. Despite these group differences, daily 
changes in serum CICP and IGF-I were strong predictors of daily changes in AKL for both 
eumenorrheic and oral contraceptive women. 
 
Our hypotheses that CICP, ICTP, and IGF-I concentrations would be lower in both groups 
during days when estradiol levels were elevated, and that greater cyclic variations in CICP, 
ICTP, IGF-I, and AKL would be observed in eumenorrheic women during and immediately 
following the peri-ovulatory days of the cycle (when estradiol is rising unopposed) were only 
partially supported. Specifically, CICP and ICTP concentrations tended to be higher during the 
days of menses in both groups (Figure 1c and d), with eumenorrheic women decreasing both 
serum CICP and ICTP concentrations (but not IGF-I values) during the peri-ovulatory and luteal 
days compared to menses, while oral contraceptive women decreased both CICP and IGF-I 
concentrations (but not ICTP) later in the cycle. However, consistent with our hypothesis, we did 
observe more acute variability across time in CICP, ICTP, IGF-I, and AKL in eumenorrheic 
women (Figure 1c vs. Figure 1d), particularly around the peri-ovulatory days, although this did 
not reach a level of significance for IGF-I. 
 
The findings in eumenorrheic women are consistent with a prior investigation of serum carboxy-
terminal propeptide of type I procollagen (PICP) and ICTP concentration changes when sampled 
on multiple days of the cycle.20 We further observed that decreases in ICTP were sustained for a 
longer period of time (into days of the early luteal phase) and to a somewhat greater magnitude 
than CICP (40% vs. 32% reduction, respectively). As can be seen in Figure 1c, these decreases in 
CICP (O1–O3, then again on EL3–LL5) and ICTP (O2-EL1, and again on EL4) occurred just 
prior to days of the cycle when AKL increased (EL1–EL3, and again on LL2, LL4, and LL5). 
This is further reinforced by our secondary findings of lower CICP levels (but not ICTP levels) 
predicting greater AKL increases. As greater ligament laxity and reduced stiffness have been 
associated with decreases in ultimate tensile forces,26, 27 these findings would appear consistent 
with the suggestion posed by Yu et al.14 that higher estradiol levels have the potential to inhibit 
collagen synthesis and ligament strength. However, the current study only measured knee laxity 
(where other capsular tissues may also contribute to the resistance to joint motion), and ligament 
properties were not directly measured. 
 
IGF-I did not change appreciably across the menstrual cycle in eumenorrheic women, although 
their values tended to vary more than oral contraceptive women (Figure 3). This was contrary to 
our hypothesis and may in part be due to the interplay between sex steroids and IGF-I which is 
poorly understood and further complicated by the normal feedback regulation observed in the 
GH–IGF-I axis. Research has shown that estradiol, while increasing GH release, inhibits the 
hepatic action of GH28 and that elevated estradiol reduces IGF-I responsiveness, such that only 
modest elevations in IGF-I occur from midcycle onward despite increased endogenous estrogen 
levels,29 exactly as observed in our eumenorrheic women. In addition, although both testosterone 
and estradiol have been shown to increase GH release, only testosterone consistently elevates 
IGF-I.28 In the current study, increases in testosterone and IGF-I followed a similar pattern in 
eumenorrheic women. 
 
While oral contraceptive women experienced a similar pattern of decrease in CICP across the 20 
days, they had no change in ICTP or AKL, but experienced progressive consistent depressions in 
testosterone and IGF-I across the latter half of the cycle. The use of exogenous estradiol in a 
variety of protocols has resulted in significant reductions in IGF-I across the latter part of the 
cycle.17–19, 29 The progressive decreases and subsequent recovery of CICP concentrations at the 
onset of menses in women using oral contraceptives is consistent with our hypotheses, and is 
also consistent with the suppression of collagen synthesis in response to the supraphysiological 
dosing of estradiol delivered in the 2nd–4th pill weeks as suggested by the findings of Yu et 
al.14 However, contrary to our hypotheses (and our findings in eumenorrheic women), ICTP 
levels remained unchanged while IGF-I levels increased. While the maintenance of relatively 
higher ICTP concentrations in oral contraceptive women is contrary to previous reports in young 
women,18, 19 the relatively higher ratio of ICTP to CICP concentrations in oral contraceptive 
women as compared to eumenorrheic women may explain the greater suppression in IGF-I in 
oral contraceptive women.30 
 
IGF-I was a strong positive predictor of cyclic AKL changes (and as can be seen from Figure 1c, 
track closely together). IGF-I is known to play an important role in the regulation of collagen 
protein synthesis.31 Specifically, IGF-I and IGF binding proteins (IGFBPs) have been shown to 
regulate collagen synthesis and degradation in vitro and IGF-I administration in adults has been 
shown to increase collagen synthesis and increase type I collagen mRNA in cultured 
cells.32 IGF-I is also considered essential for wound healing as decreased IGF-I concentrations 
profoundly inhibited tissue repair.33 Additionally, IGF-I increased both PINP and ICTP 
concentrations and an inverse correlation was observed between the ICTP:PINP ratio and IGF-
I.30 Together, these findings suggest that while IGF-I favors collagen synthesis/deposition—or at 
the very least, protects against excessive breakdown of collagen—it clearly plays a role in 
collagen turnover, altering both synthesis and degradation. When considering this literature, the 
positive associations we observed between IGF-I and AKL may represent a compensatory 
increase in IGF-I following suppression of both ICTP and CICP in order to stimulate collagen 
synthesis and prevent further tissue breakdown, or it may reflect the fact that increased IGF-I 
results in greater turnover of collagen. Further, it is well accepted that type I collagen turnover 
originates from several tissues, with ligament being just one, relatively small, contributor. Thus, 
it is possible that the association we are observing simply represents a data “artifact” due to IGF-
I being a major controller for collagen turnover in general (bone, as well as ligament), and that 
both IGF-I and AKL are not directly related, but rather are responding to a similar, unidentified 
underlying process. Further work is needed to understand the complex role of IGF-I (i.e., local 
vs. systemic) in collagen homeostasis and ligament integrity local to the knee joint. 
 
Comparisons of our findings in oral contraceptive women to prior research is difficult given the 
different types of oral contraceptives the women under study were using (e.g., monophasic vs. 
triphasic; the varying potency and adrogenicity of progestogen compounds in different 
preparations; and the varying dosages of estradiol),16 the limited number of time points 
compared, and difficulty in quantifying serum concentrations of the exogenous hormones 
delivered. For example, Hansen et al.18 compared days 18–21 in oral contraceptive women to 
early follicular days in eumenorrheic women. They reported lower concentrations of a urine 
marker of type I collagen synthesis and similar concentrations of a urine marker of type I 
collagen degradation in oral contraceptive versus eumenorrheic women. As noted in 
Figures 4 and 5, the lower type I collagen synthesis reported in oral contraceptive women may 
have simply resulted from the different test days examined, as CICP values were substantially 
lower at the end of the cycle compared to menses in both groups. In other work, a clear decrease 
in markers of collagen synthesis and degradation were observed in women on days 21–24 of 
their cycle from before to after 3 months of oral contraceptive administration.19 In this study, all 
women used the same monophasic oral contraceptive (desogestrel 150 mg and ethinyloestradiol 
30 mg), where the progestogen has relatively high potency and androgenicity that can produce 
more potent masculine effects and counteract estrogenic effects to a larger extent.16, 34 
 
In the current study, women used a variety of oral contraceptives that included progestogens with 
lower potency and androgenicity. To examine whether these different progestogens may in part 
explain the higher overall serum collagen marker concentrations we observed in oral 
contraceptive versus eumenorrheic women, we ran secondary bivariate correlations between the 
mean potency and androgenicity of the oral contraceptive used by each woman and her mean 
CICP, ICTP, and IGF-I concentrations. While there was little to no relationship between the 
potency of the progestogen and these serum concentrations (r range = −0.092 to 
−0.247, p >0.492), progestogens with a greater androgenicity were associated with lower mean 
ICTP (−0.751, p = 0.012) and IGF-I (−0.605, p = 0.064) concentrations, but not CICP 
concentrations (r = 0.183, p = 0.462). Hence, the magnitude of suppression in collagen 
production and degradation mediated by oral contraceptives may depend on the progestogen 
compound used, and should be appropriately accounted for in future research. 
 
Despite these differences, the suppressed IGF-I concentrations we observed in our oral 
contraceptive women have been associated with lower collagen synthesis and a smaller collagen 
fibril diameter in tendons in other oral contraceptive women, which is thought to be suggestive 
of a more inferior collagen structure.17, 18 Thus, it is somewhat surprising that we did not observe 
cyclic changes in AKL in our oral contraceptive women, despite the fact that CICP 
concentrations decreased in both groups, and lower CICP concentrations and higher IGF-I 
concentrations were strongly associated with AKL within both groups. This would seem to 
suggest that mechanisms involving the inter-play between serum CICP and IGF-I concentrations 
may be important. This is based on observations that increases in AKL were primarily observed 
in eumenorrheic women following the peri-ovulatory days of the cycle when CICP (as well as 
ICTP) concentrations were suppressed, which were followed by an observable (but statistically 
insignificant) increase in both AKL and IGF-I (Figure 1c). Further, the suppression in CICP and 
ICTP were of greater magnitude and variability than what was observed in oral contraceptive 
women (see Figure6). Conversely, both CICP and IGF-I concentrations gradually decreased in 
oral contraceptive women, with no corresponding change in AKL. These differential findings 
were initiated in the peri-ovulatory days when only eumenorrheic women experienced 
unopposed increases in estradiol, while oral contraceptive women were exposed to elevated 
levels of both estradiol and progesterone that remained relatively consistent across the pill days 
as compared to menses. Thus, the inhibitory effect of estradiol on collagen synthesis (and other 
important mechanistic processes not studied) may have been attenuated in oral contraceptive 
women given their concurrent rises in progesterone and their relative consistency in 
concentration levels across multiple days.14 However, because the pharmacokinetics and biologic 
effects of the various oral contraceptive preparations are not well known,16 and our assay 
techniques did not allow us to account for both endogenous and exogenous hormone 
concentrations, these interpretations remain largely theoretical. Further research should confirm 
the direct and indirect mechanisms that may underlie these associations, as well as the extent to 
which the type of exogenous progestin delivered in the oral contraceptive influences the 
attenuation of estrogenic effects16 on collagen metabolism. 
 
In summary, although this study represents a fairly rudimentary first step in attempting to 
understand the mechanisms by which hormone concentration changes lead to changes in knee 
laxity, our findings tend to support (more than refute) the theories emanating from in vitro 
models that increasing estradiol concentrations have the potential to influence collagen synthesis 
and ligament integrity in a negative manner. However, much remains unknown about these 
underlying mechanistic processes, which limits clear interpretation of these findings. First, the 
associations observed in this study are limited to serum (systemic) biomarkers, which may or 
may not represent the local environment of the ligament, as changes in type I collagen from other 
tissues (e.g., bone) largely contribute to circulating serum concentrations.17, 18 This study is also 
limited to the assessment of biomarkers for type I synthesis and degradation, and biomarkers for 
other collagen types relevant to ligament structure and function (e.g., type III, V, XII) should 
also be examined in future studies. The temporal sequencing of changes in sex hormones, 
changes in serum collagen markers, and changes in knee laxity also cannot be adequately 
determined from the current study (this would likely require continuous collection over three 
consecutive cycles), which limits the interpretation of our findings, particularly for the regression 
analyses. It is appreciated that complex intermediate processes may drive these associations, and 
that there could reasonably be time lags between respective changes in sex hormones, collagen 
metabolism and soft tissue behavior. While a 3- to 5-day time lag was observed between sex 
hormone changes and knee laxity changes in prior work,5 this was quite variable among women 
and was limited to time lags within a single cycle. Further, we were unable to locate literature 
that has examined the temporal changes between serum sex hormone concentration changes and 
serum collagen marker changes, in vivo. Because of these limitations, it is difficult to fully 
rectify the sequencing of these events to the times in the cycle when ACL injury risk appears to 
be elevated.16 Despite these limitations and the many unknowns that remain, our initial findings 
suggest that further research examining these mechanisms is warranted, as cyclic increases in 
knee laxity (and decreases in stiffness) across the menstrual cycle may be characteristic of a 
weaker ligament26, 27, 35 and lead to higher risk knee joint biomechanics,36 which together may 
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